Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry-Reference-Cited by-同舟云学术

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:1859-1861
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lemoine Jean¹,Bachy Emmanuel²,Cartron Guillaume³,Beauvais David⁴,Gastinne Thomas⁵,Rubio Marie Thérèse⁶,Leleu Xavier⁷,Mohty Mohamad⁸,Casasnovas René-Olivier⁹,Joris Magalie¹⁰¹¹,Castilla-LLorente Cristina¹²¹³,Haioun Corinne¹⁴¹⁵,Hermine Olivier¹⁶,Loschi Michael¹⁷,Carras Sylvain¹⁸,Bories Pierre¹⁹,Fradon Tom²⁰,Herbaux Charles²¹²²,Sesques Pierre²³,Le Gouill Steven²⁴,Morschhauser Franck²⁵,Thieblemont Catherine²⁶,Houot Roch²⁷

Affiliation:

1. 1Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Hemato-oncologie; Université de Paris, Paris, France

2. 2Hematology Department, Hospices Civils de Lyon; Lymphoma Immuno-Biology (LIB) Team, Université Claude Bernard Lyon 1, Lyon, France

3. 3Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France

4. 4Department of Hematology, University Hospital of Lille, Lille, France

5. 5Hematology Department, Nantes University Hospital, Nantes, France

6. 6Hematology Department, University Hospital of Nancy, Vandoeuvre, France

7. 7Department of Oncology, Hematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France

8. 8Department of Haematology, Saint Antoine Hospital, Paris, France

9. 9Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France

10. 10Service d'Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d'Amiens, Amiens, France

11. 11CHU Amiens, Amiens, France

12. 12Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France

13. 13Department of Hematology and INSERM UMR 1030, Université Paris-Saclay, Gustave Roussy Cancer Campus Grand Paris, Paris, France

14. 14Lymphoid Malignancies Department, Henri Mondor University Hospital/Assistance Publique-Hôpitaux de Paris (AP-HP)/Université Paris-Est Créteil (UPEC), Creteil, France

15. 15Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil, France

16. 16Clinical Hematology, Necker University Hospital, Paris, France

17. 17Hematology department, CHU de Nice, Universite Cote d'Azur, Nice, France

18. 18Centre Hospitalier Universitaire Grenoble, La Tronche, FRA

19. 19Department of Hematology, Toulouse University Institute of Cancer, Toulouse, France

20. 20Lymphoma Academic Research Organisation, Pierre-Benite, France

21. 21CHU de Montpellier, Montpellier, France

22. 22Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France

23. 23Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre Benite, France

24. 24Service d'hématologie clinique, CHU de Nantes, Nantes, France

25. 25Centre Hospitalier Régional Universitaire De Lille, Lille, FRA

26. 26Department of Hemato-Oncology, Saint Louis Hospital, Paris, France

27. 27Clinical Hematology, University Hospital Pontchaillou, Rennes Cedex, FRA

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies;Transplantation and Cellular Therapy;2024-07

2. Unselected donor‐derived hematopoietic stem cells boost for Chimeric Antigen Receptor T‐cell associated hematotoxicity;American Journal of Hematology;2024-01-22

3. Long‐term survivorship care after CAR‐T cell therapy;European Journal of Haematology;2023-09-28

4. Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic;Bone Marrow Transplantation;2023-09-04

5. Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management;European Journal of Haematology;2023-07-25